BiotechTube

Etonogestrel contraceptive implant

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Contraception

Conditions

Contraception

Trial Timeline

Aug 13, 2020 → Apr 9, 2024

NCT ID
NCT04423055

About Etonogestrel contraceptive implant

Etonogestrel contraceptive implant is a approved stage product being developed by Merck for Contraception. The current trial status is completed. This product is registered under clinical trial identifier NCT04423055. Target conditions include Contraception.

What happened to similar drugs?

14 of 20 similar drugs in Contraception were approved

Approved (14) Terminated (1) Active (6)
✅Rifampin 600 MGMerckApproved
✅Long Acting Reversible Contraception (LARC)MerckApproved
✅Etonogestrel contraceptive implantMerckApproved
✅Sayana PressPfizerApproved
✅Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
✅Subcutaneous depot medroxyprogesterone acetatePfizerApproved
✅Levonorgestrel (Mirena, BAY86-5028) + Cytotec + PlaceboBayerApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04423055ApprovedCompleted
NCT02852265ApprovedCompleted

Competing Products

20 competing products in Contraception

See all competitors
ProductCompanyStageHype Score
Injection CyclofemSun PharmaceuticalPhase 1/2
32
Relugolix Combination TherapySumitomo PharmaPhase 3
44
Transdermal Contraceptive System + Norgestimate-containing oral contraceptives with EEJohnson & JohnsonPre-clinical
26
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.Johnson & JohnsonPhase 1
29
norelgestromin + ethinyl estradiolJohnson & JohnsonPhase 3
40
norelgestromin + ethinyl estradiol; triphasil.Johnson & JohnsonPhase 3
40
norelgestromin + ethinyl estradiol; mercilonJohnson & JohnsonPhase 3
40
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
29
EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EEJohnson & JohnsonPhase 1
29
Monophasic or triphasic Oral contraceptive tablet + Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EEJohnson & JohnsonPre-clinical
26
Norgestimate/Ehinyl Estradiol; Folic acid.Johnson & JohnsonPhase 1
29
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).Johnson & JohnsonPhase 1
29
oral ulipristal acetateMerckPhase 1
29
Rifampin 600 MGMerckApproved
43
Long Acting Reversible Contraception (LARC)MerckApproved
35
Etonogestrel contraceptive implantMerckApproved
43
Medroxyprogesterone 17-Acetate + Medroxyprogesterone 17-AcetatePfizerPre-clinical
26
Sayana PressPfizerApproved
43
Levonorgestrel 90 mg/Ethinyl Estradiol 20 mgPfizerPhase 3
40
Depo-Provera Contraceptive Injection - DP150CIPfizerApproved
43